# Integrated Pulmonary Severity Score (IPSS) for COPD: A Psycho-Respiratory Risk Index Supported by Explainable Machine Learning

**Authors:** Iulian-Laurențiu Buican, Alina-Catalina Buican-Chirea, Dumitru Radulescu, Ion Udristoiu, Victor Gheorman, Dragos-Mihai Cojocaru, Costin-Teodor Streba

PMC · DOI: 10.3390/diagnostics16040507 · 2026-02-07

## TL;DR

A new score called IPSS combines lung function, symptoms, and mental health to better assess COPD severity, using machine learning to identify a group with combined respiratory and psychological issues.

## Contribution

The IPSS integrates respiratory and psychological factors into a single severity score for COPD, supported by explainable machine learning.

## Key findings

- IPSS identified a psycho-respiratory COPD phenotype with lower lung function and higher symptom and anxiety scores.
- Machine learning models achieved high accuracy (0.89) and AUC (0.95) in identifying the psycho-respiratory phenotype.
- IPSS values were stratified into four severity levels, reflecting combined respiratory and affective burden.

## Abstract

Background/Objectives: In chronic obstructive pulmonary disease (COPD), forced expiratory volume in one second (FEV1) explains only part of the variability in symptoms and prognosis, while anxiety and depression are common but rarely quantified in composite indices. We aimed to develop and internally validate an Integrated Pulmonary Severity Score (IPSS) that combines respiratory function, symptom burden and affective status. Methods: In a prospective observational study, 390 adults with spirometry-confirmed COPD were consecutively enrolled at two tertiary Romanian centres (October 2022–September 2024). Within 48 h of admission, patients underwent spirometry (FEV1% predicted), dyspnoea grading (mMRC), symptom assessment (CAT), affective evaluation (HADS-Anxiety/Depression) and cognitive screening (MoCA, MMSE). A PulmoScore was built from CAT, mMRC and ventilatory deficit (100 − FEV1%) and extended with a HADS-based psychiatric multiplier to obtain IPSS. Spectral clustering, logistic regression, a multilayer perceptron (MLP) and LIME were used for phenotyping and validation. Results: Spectral clustering identified two phenotypes—psycho-respiratory and predominantly respiratory—with acceptable separation (silhouette coefficient 0.26). The psycho-respiratory group showed lower FEV1%, higher CAT and mMRC scores, more severe anxiety–depression and markedly higher IPSS values. Logistic regression and the MLP achieved an accuracy of 0.89, an AUC of 0.95 and Cohen’s κ ≥ 0.75 for identifying this phenotype when using the same core clinical variables that informed phenotyping and IPSS construction. IPSS values were distributed across four strata (<30, 30–69, 70–119, ≥120 points), reflecting progressively worse respiratory and affective burden. Conclusions: In this cohort, IPSS captured a clinically meaningful psycho-respiratory phenotype and improved integrated severity assessment beyond spirometry alone, with potential utility for risk stratification. It can be computed from routine measures, is compatible with explainable AI workflows and warrants external, longitudinal validation before widespread implementation.

## Linked entities

- **Diseases:** chronic obstructive pulmonary disease (MONDO:0005002), COPD (MONDO:0005002)

## Full-text entities

- **Genes:** CAT (catalase) [NCBI Gene 847], FOXO1 (forkhead box O1) [NCBI Gene 2308] {aka FKH1, FKHR, FOXO1A}, AVP (arginine vasopressin) [NCBI Gene 551] {aka ADH, ARVP, AVP-NPII, AVRP, VP}, MIR132 (microRNA 132) [NCBI Gene 406921] {aka MIRN132, miRNA132, mir-132}, SIRT1 (sirtuin 1) [NCBI Gene 23411] {aka SIR2, SIR2L1, SIR2alpha}, NFKB1 (nuclear factor kappa B subunit 1) [NCBI Gene 4790] {aka CVID12, EBP-1, KBF1, NF-kB, NF-kB1, NF-kappa-B1}, SIRT6 (sirtuin 6) [NCBI Gene 51548] {aka SIR2L6, hSIRT6}, TREM1 (triggering receptor expressed on myeloid cells 1) [NCBI Gene 54210] {aka CD354, TREM-1}
- **Diseases:** sleep apnoea (MESH:D012891), related functional limitation (MESH:D045745), immune dysregulation (OMIM:614878), sepsis (MESH:D018805), IPSS (MESH:D045169), cognitive decline (MESH:D003072), heart failure (MESH:D006333), IV (MESH:D006011), Depression (MESH:D003866), obstructive sleep apnoea (MESH:D020181), autoimmune thyroiditis (MESH:D013967), hypersensitivity (MESH:D004342), cough (MESH:D003371), microvascular (MESH:D017566), respiratory symptoms (MESH:D012818), dual impairment (MESH:D009105), death (MESH:D003643), affective distress (MESH:D012128), exertional limitation (MESH:C564288), pulmonary obstruction (MESH:D011655), obstruction (MESH:D000402), damage (MESH:D020263), non-small cell lung cancer (MESH:D002289), obesity (MESH:D009765), respiratory comorbidity (MESH:D012131), pulmonary function (OMIM:608852), GOLD I (MESH:D006969), immune-mediated inflammatory disorder (MESH:C567355), COPD (MESH:D029424), chest tightness (MESH:D002637), pulmonary disease (MESH:D008171), Psychiatric (MESH:D001523), breathlessness (MESH:D004417), asthma (MESH:D001249), Anxiety (MESH:D001007), declining lung function (MESH:D055370), cardiometabolic comorbidities (MESH:D024821), injury to (MESH:D014947), inflammation (MESH:D007249), emotional disturbance (MESH:D014832), respiratory disease (MESH:D012140)
- **Chemicals:** alcohol (MESH:D000438), pembrolizumab (MESH:C582435)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Figures

7 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12939995/full.md

---
Source: https://tomesphere.com/paper/PMC12939995